Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00287339
Other study ID # AZ COUGH
Secondary ID
Status Completed
Phase Phase 4
First received February 3, 2006
Last updated January 6, 2012
Start date September 2005
Est. completion date September 2008

Study information

Verified date January 2012
Source University of North Carolina, Chapel Hill
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug AdministrationUnited States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this research study is to investigate different doses of proton pump inhibitors in reducing cough symptoms felt to be associated with Gastroesophageal reflux disease (GERD). Proton pump inhibitors are medicines used to treat GERD, which work by lowering the amount of acid in the stomach.

The proton pump inhibitor used in this study is called, Esomeprazole (brand name Nexium), and is already marketed for treating GERD. Patients with GERD may experience all or some of the following symptoms: stomach acid or partially digested food re-entering the esophagus (which is sometimes referred to as heartburn or regurgitation), belching and coughing. Even very small, unnoticeable amounts of rising stomach acid may cause patients to cough.

Because there may be a link between chronic cough and GERD, study doctors are interested in learning if giving high-dose Nexium (40 milligrams, twice daily) will help in treating chronic cough.


Description:

This study will be a randomized, double-blind, placebo controlled, comparative parallel-group trial of subjects with chronic cough of unknown origin presenting to the Otolaryngology/ Head and Neck Surgery, Pulmonary Medicine, and Gastroenterology outpatient clinics at the University of North Carolina Hospital system.

Potential subjects with chronic cough of unknown origin will be identified through the above outpatient clinics. Those who meet the inclusion and exclusion criteria will be asked to join the study testing the efficacy of twice daily esomeprazole 40 mg taken for 3 months in the setting of chronic cough. Potential subjects will be consented for the study prior to leaving the enrolling clinic. A total of 40 subjects will be recruited into our study.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date September 2008
Est. primary completion date September 2008
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

1. males and females (of non-childbearing potential. ie-surgically sterile, or willing to use an approved form of birth control) between the ages of 18 and 70 who speak and write in English,

2. chronic cough (> 8 wks/another article used > 6 wks) with symptom severity criteria of 2 or greater on the Fisman Cough Severity Score and 3 or greater or the Fisman Cough Frequency Score, and,

3. failure to respond to post nasal drip therapy.

Exclusion Criteria:

1. abnormal chest x-ray,

2. patients taking H2 blockers within the previous 3 days or PPI's within the previous 7 days,

3. failure to respond to past PPI therapy given for cough that lasted at least 12 weeks,

4. use of an investigational drug within the past 30 days,

5. previous surgical antireflux or non-surgical endoscopic anti-reflux procedure (ex., Stretta or endoscopic sewing device),

6. previous aerodigestive malignancy,

7. current smokers, or ex-smokers (defined as those who quit smoking less than 3 months prior to study enrollment or those who have quit, but have a 20 pack year smoking history),

8. upper respiratory infection within 8 weeks prior to study enrollment,

9. current use of a B- blocker, ACE-I, or anticholinesterases at time of enrollment.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Esomeprazole
40mg capsule BID for 12 weeks
Placebo
placebo capsule BID for 12 weeks

Locations

Country Name City State
United States UNC Gastroenterology, UNC Pulmonology, UNC ENT Chapel Hill North Carolina

Sponsors (2)

Lead Sponsor Collaborator
University of North Carolina, Chapel Hill AstraZeneca

Country where clinical trial is conducted

United States, 

References & Publications (1)

Shaheen NJ, Crockett SD, Bright SD, Madanick RD, Buckmire R, Couch M, Dellon ES, Galanko JA, Sharpless G, Morgan DR, Spacek MB, Heidt-Davis P, Henke D. Randomised clinical trial: high-dose acid suppression for chronic cough - a double-blind, placebo-contr — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Cough-Specific Quality of Life Questionnaire It is a validated, 28-item assessment tool designed to evaluate decrements in quality of life due to chronic cough. This questionnaire measures cough-related symptoms, as well as the social implications and psychological impact. Examples of items include, "I cannot sleep at night" and "I cough and it makes me retch." The final score is obtained by summing the responses to 28 questions, each scored on a 1-4 scale, where 1 is "strongly disagree," and 4 is "strongly agree." The minimum and maximum CQLQ scores are 28 and 112 respectively, with increasing score indicating more severe impairment. baseline and 12 weeks No
See also
  Status Clinical Trial Phase
Completed NCT00116337 - Spinal Cord Stimulation to Restore Cough N/A
Not yet recruiting NCT04064333 - Slow-Stream Expiratory Muscle Strength Training for Veterans With Dysphagia Living in Long-term Care N/A
Recruiting NCT02482818 - Efficacy of Pregabalin on Chronic Cough Phase 1/Phase 2
Terminated NCT02269761 - Chest Ultrasound of ER Patients With Cough or SOB
Active, not recruiting NCT02065440 - The Effect of Ebastine/Pseudoephedrine on Subacute Cough N/A
Completed NCT01071161 - The Effect of Azithromycin in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Productive Cough Phase 3
Completed NCT00353951 - An Observational Study of Cough / Lower Respiratory Tract Infection (LRTI) in Primary Care N/A
Terminated NCT00668317 - Bronchial Hyper-responsiveness in Reflux Cough Phase 3
Completed NCT00127686 - Effect of Honey and Dextromethorphan on Nocturnal Cough and Sleep Phase 1
Recruiting NCT05115097 - AI Evaluation of COVID-19 Sounds (AI-EChOS)
Recruiting NCT04457011 - Efficacy and Safety of Susu Zhike Granules for Treating Acute Cough Due to Common Cold With Cold-cough Syndrome in Children Phase 2
Recruiting NCT05042063 - Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease
Recruiting NCT03922373 - A Study of Benzonatate Soft Capsule in Chinese Healthy Subjects Phase 1
Completed NCT05812209 - Stellate Ganglion Block to Treat Long COVID 19 Case Series
Recruiting NCT04767074 - A Non-pharmacological Cough Control Therapy N/A
Recruiting NCT05570539 - Assessment of the Pharmacokinetics of BLU-5937 Extended Release Prototypes and a BLU-5937 Immediate Release Reference Formulation Phase 1
Completed NCT03999203 - A Cross-sectional Study to Measure Cough in Severe Asthma N/A
Active, not recruiting NCT05479929 - Work of Breathing Assessment in Triage Scale
Recruiting NCT02495571 - Assessment of Voluntary and Reflex Cough in Patients With ALS N/A
Completed NCT02183519 - Respiratory Kinematics of Cough in Healthy Older Adults and Parkinson's Disease Phase 1/Phase 2